Kentucky sues J&J over Risperdal marketing; Novartis' Afinitor works in Herceptin combo trial;

breast cancer

@FiercePharma: Biopharma's 20 highest-paid CEOs. Our latest special report on exec pay. Report | Follow @FiercePharma

@EricPFierce: AstraZeneca rides Crestor to top of cardio drug list. Special report | Follow @EricPFierce

> Kentucky's attorney general has added his lawsuit to the list of state claims filed against Johnson & Johnson ($JNJ) alleging illegal marketing of its Risperdal antipsychotic drug. 

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

> Novartis ($NVS) said its Afinitor cancer treatment extended progression-free survival in women with HER2 positive breast cancer when used in combination with Roche's ($RHHBY) Herceptin and the chemo drug vinorelbine, compared with patients on Herceptin and vinorelbine alone. Release

> Chugai Pharmaceutical CEO Osamu Nagayama is said to be getting a new post: chairman of Sony Corp. Report

> The new "bible" of psychiatry, the controversial fifth version of the Diagnostic and Statistical Manual of Mental Disorders, may find itself less influential than previous editions, particularly in research. Report

> Teva Pharmaceutical Industries ($TEVA) is trying to keep clear of the political controversy surrounding its Plan B contraceptive and girls' access to it. Report

Medical Device News

@FierceMedDev:  Shoe-mounted lever could power artificial heart pumps. More | Follow @FierceMedDev

@MarkHFierce: Check out FierceDrugDelivery's latest - a great look at some advances in nanotech drug delivery. Special report | Follow @MarkHFierce

 @DamianFierce:  PRA is lining up to go public, filing a confidential draft with the SEC. Article | Follow @DamianFierce

> FDA slaps deadly label on Abbott's glucose meter recall. News

> PIP attorneys plead for leniency in breast implant fraud trial. Report

> Medtronic wins CE mark for clot-removal tech. More

Biotech News

@FierceBiotech:  Life sciences VC firm launches 'crowdfunding' site for limited crowd. More | Follow @FierceBiotech

@JohnCFierce: Pentagon advisor pocketed biotech's cash while promoting its interests - via LATimes. Report | Follow @JohnCFierce

@RyanMFierce: Interesting 'Open Research Exchange' platform debuts for creating outcome measures from the crowd. Release | Follow @RyanMFierce

> Pentagon adviser quietly pocketed biotech's cash while promoting its interests. Story

> Elan orchestrates $693M biotech buyout, $90M spinout in deal frenzy. Report

> Effector Therapeutics snags $45M venture round from A-list backers. News

CRO News

> Nordion inks CMO deal with Navidea. Report

> After successful IPO, Quintiles plots 400 job cuts. Item

> PRA winds up for IPO. News

> Quintiles signs on to help Merck KGaA right the R&D ship. More

> PPD's BioDuro opens Shanghai discovery lab. Story

>WuXi's revenue jumps 11.7% in strong Q1. Article

Biotech IT News

> Drugmaker UCB taps IBM for digital medicine effort. Article

> InSilico Genomics grabs $1.5M for fledgling bioinformatics biz. Report

> Life sciences VC firm launches 'crowdfunding' site for limited crowd. Article

> Sanofi hunts for clinical trial recruits in growing social network. Story

> Merck targets docs with revamped U.K. website and healthcare apps. News

And Finally... U.K. Health Secretary Jeremy Hunt called for international action to deal with the soaring number of antibiotic-resistant infections. Release

Read more on

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.